A prospective study was undertaken to evaluate the efficacy of (sodium) cromoglycate in the treatment of persistent wheezing in 31 children between 4 and 12 months of age. The subjects were randomised to receive either 40 mg of cromoglycate (n= 16) or physiological saline as placebo (n= 15) Patients who met the initial inclusion criteria were discharged with an agenda with week 0 beginning on the day of the initial encounter. Daily respiratory signs and symptoms that included cough, wheeze, thoracic indrawing, and sleep pattern, were recorded for a period of three weeks; the score assigned to each of these parameters is shown in table 1. Parents were instructed on the administration of salbutamol (Ventolin, Glaxo) Od15 mg/kg by wet nebulisation technique using a Hudson Updraft II nebuliser (particle mass median diameter of 3-4 microns) powered by a DeVilbiss Pulmo-Aide air compressor supplying 5 I/min of compressed air and a facemask. Salbutamol was given every 4-6 hours as
Respiratory exacerbation requiring additional medication other than salbutamol during the baseline period resulted in withdrawal from the study. Hospital admissions during the study period were noted but were not cause for withdrawal.
Patients were evaluated three and six weeks after randomisation, that is, six and nine weeks from baseline respectively. While parents were asked to complete the agenda throughout the study, the score at the six week evaluation was not used in the statistical analysis. The baseline symptom score was compared with that obtained at week 9, that is, the final symptom score (the symptom score recorded daily during the final three weeks of the study from week 6 to week 9). Similarly, pulmonary function tests were also compared at these two time points.
Compliance was assessed at the six week and nine week visit by a count of the unused medication vials returned at each visit and agenda card verification. Between each evaluation, compliance was encouraged via telephone by one of the investigators (SPD). Unpaired Student's t test was used to assess variability between the active and placebo groups for lung function and symptom score at both baseline and after treatment times. Paired Student's t test was employed to assess the variability within each group between baseline and after treatment for lung function and symptom score. In addition, non-parametric methods were also used to test for potential differences between total symptom scores at baseline and after treatment; Wilcoxon signed rank test for within group comparisons and Mann-Whitney U test for between group comparisons. Both the non-parametric and parametric analyses resulted in similar levels of significance for both the baseline and after treatment total symptom score. In order to discriminate an improvement of two units/day in the symptom score, we required a sample size of 24 patients. A minimum of six patients per stratum was needed to show a difference of two points on the daily clinical score with a one sided type I and type II error of 005 and 0-20 respectively. Therefore, the total sample size required was 24 patients. The level of significance was set at p<0 05. All results are represented as the mean (SD) unless otherwise specified.
Written informed consent was obtained from the parents and this study was approved by the ethics committee of Ste Justine Hospital.
Results
Thirty seven patients were randomised into the study. Three patients were excluded from final analysis because of parental withdrawal and three others were excluded due to poor compliance. No significant difference in the baseline status was found between those excluded and the study population. The demographics of the remaining 31 patients are shown in table 2. There were no statistically significant differences between the control and the study group for any of the baseline parameters evaluated. There were three nose breathers and six mouth breathers in the cromoglycate Efficacy of cromoglycate in persistently wheezing infants Significant improvement of the symptom score was present within both the placebo and the cromoglycate group. Similarly, the pulmonary function tests within each group displayed a trend towards improvement but did not reach statistical significance.
The data were analysed with respect to each age stratification. There was no difference in symptom score or pulmonary function improvement between the cromoglycate and placebo group in both the 8-12 month subgroup and the 4-8 month group. Salbutamol was administered in a comparable fashion in both study groups during the study. This symptom score was recorded by the parents on a daily basis. Those who appeared to respond to cromoglycate, based on parental judgment, had an average age of 16-4 months. Pulmonary function testing was not performed in this study. In a younger subgroup of patients (age non-specified) from this same study, however, cromoglycate was determined by the parents to be ineffective.
Similarly, we also found that cromoglycate was ineffective in children under 1 year of age. As Henry et al had shown that cromoglycate appeared effective in the older children of his study population,5 we stratified our study population within the sodium cromoglycate and placebo groups according to age, arbitrarily taking 8 months as a cut off point. Even when considering the children greater than 8 months of age at the onset of the study, we were unable to show a beneficial effect of cromoglycate.
Many factors in this age group can contribute to the non-efficacy of cromoglycate, including poor delivery to the lung due to anatomical considerations, method of administration, and nasal breathing. Furthermore, duration of administration can influence efficacy. Cromoglycate when given for less than six weeks shows no reduction in bronchial hyperreactivity in 7/1 1 studies.9 We administered cromoglycate for six weeks, which is a reasonable trial.'0 Salmon et al suggested that young children may be difficult to treat because inadequate amounts of drug reach the lung."I In their study, less than 1% of a 20 mg dose of cromoglycate administered by wet nebulisation was absorbed as measured by urinary excretion of the drug in children between 9 and 36 months of age. Furthermore, this amount may even be considered to be an overestimation as some of the cromoglycate may be absorbed through the nasal mucosa. As infants are predominantly nose breathers, the nose may act as a filter reducing pulmonary deposition to a quarter of the value obtained during mouth breathing."
While this may have occurred in our patients, the number of nose breathers in both groups It is interesting that the symptom score improved significantly within each group. As one might expect in asthma, the evolution of wheezing in infants over a period of six weeks seems to be one of spontaneous resolution.
Pulmonary function testing as measured by the squeeze technique was performed on our patients. While this test does not represent the respiratory status of the patient throughout the whole treatment period, it permitted an objective measurement of lung function on two different occasions and demonstrated comparable improvements within the two groups. Although, we are aware that this test has limitations,'8 we attempted to minimise the influence of these factors on our results by adhering to a standardised protocol. 6 In conclusion, cromoglycate administered by wet nebulisation at a dosage of 40 mg three times a day was no more effective than placebo in the treatment of our sample of persistently wheezing infants under 1 year of age. In addition, this study does not support the current recommendation of the consensus report.2 wheezing infants. 
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